AvidBiologics Closes New Financing Round

Ontario Industry Updates
Written By obio

TORONTO (Sept. 29, 2014) — AvidBiologics Inc., an oncology drug development company, today announced the closing of a financing round. The company is founded on antibody-drug conjugate (ADC) technologies co-developed with the National Research Council of Canada (NRC). Led by Lumira Capital, the financing round included MaRS Investment Accelerator Fund (IAF), MaRS Innovation (MI), Rosseau Asset Management, and the company’s founding investors. Today’s financing builds on prior support from the Ontario Centres of Excellence (OCE), the National Research Council of Canada’s Industrial Research Assistance Program (NRC-IRAP), Ontario Ministry of Research and Innovation’s Business Accelerator Program (MRI-BAP) and other Canadian life science development organizations.

Click here to view the full news release.

obio
Previous

Rna Diagnostics Awarded Patent for Test that Guides Cancer Chemotherapy
Next

AbCelex Technologies Inc. Secures an Additional $1 Million in Series A Financing